ProfileGDS5678 / 1429617_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 75% 82% 78% 76% 76% 75% 75% 75% 76% 79% 76% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0802476
GSM967853U87-EV human glioblastoma xenograft - Control 24.9669675
GSM967854U87-EV human glioblastoma xenograft - Control 34.9951875
GSM967855U87-EV human glioblastoma xenograft - Control 46.154582
GSM967856U87-EV human glioblastoma xenograft - Control 55.34378
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0205576
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0556176
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.020175
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9501475
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9547475
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1267876
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5199379
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1350776
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7918974